What Has Been the Growth of the Endoscopic Retrograde Cholangiopancreatography (ERCP) Market So Far?
The endoscopic retrograde cholangiopancreatography (ercp) market has seen considerable growth due to a variety of factors.
• In the past few years, the market size for endoscopic retrograde cholangiopancreatography (ERCP) has seen significant growth. From 2024 to 2025, it is projected to increase from $1.72 billion to $1.87 billion, registering a compound annual growth rate (CAGR) of 8.87%.
The growth observed in historical periods can be associated with several factors such as an increase in chronic gastrointestinal diseases, heightened usage of ERCP procedures, a surge in pancreatic cancer incidences, increased government investment and a boost in medical tourism.
What is the Market Size Forecast for the Endoscopic Retrograde Cholangiopancreatography (ERCP) Market?
The endoscopic retrograde cholangiopancreatography (ercp) market is expected to maintain its strong growth trajectory in upcoming years.
• In the coming years, the endoscopic retrograde cholangiopancreatography (ERCP) market is projected to experience significant growth. The market value is anticipated to rise to $2.60 billion by 2029, with a compound annual growth rate (CAGR) of 8.58%.
This growth during the forecast period can be associated with the increasing occurrence of gastrointestinal conditions, higher cancer rates, amplified concentration on investments, increasing cases of pancreatic duct abnormalities, and a growing demand for endoscopes. The forecast period is also expected to see key trends like technological progress, R&D partnerships, improvements in healthcare infrastructure, the growth of government healthcare, and the creation of advanced products.
What Key Factors and Trends are Driving the Growth of the Endoscopic Retrograde Cholangiopancreatography (ERCP) Market?
The escalating occurrence of gastrointestinal disorders is predicted to fuel advancements in the endoscopic retrograde cholangiopancreatography (ERCP) market. These disorders, which can impact numerous organs in the gastrointestinal (GI) tract including the mouth, esophagus, stomach, small and large intestines, rectum, and anus, along with related organs like the liver, gallbladder, and pancreas, are seeing a rise in prevalence. This upsurge is believed to be due to a myriad of factors including changes in diet, an ageing population, antibiotic usage, lifestyle aspects, and environmental impacts. ERCP offers a less invasive solution to diagnosing and treating conditions affecting the bile and pancreatic ducts such as gallstones, strictures, tumors, or infections. As an example, in January 2024, the American Cancer Society, a non-profit organization based in the U.S., projected that approximately 26,890 new cases of stomach cancer would occur in the U.S., resulting in an estimated 10,880 deaths from this specific type of cancer. Thus, the growing frequency of gastrointestinal disorders is propelling the growth and development of the ERCP market.
What Are The Major Segments Within The Endoscopic Retrograde Cholangiopancreatography (ERCP) Market?
The endoscopic retrograde cholangiopancreatography (ERCP) market covered in this report is segmented –
1) By Product: Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices
2) By Disease Indication: Gastroesophageal Reflux Disease (GERD), Gastrointestinal Cancer, Barrett's Esophagus, Bile Duct Diseases, Peptic Ulcer Disease, Crohn's Disease, Intestinal Pseudo-Obstruction, Ogilvie Syndrome, Other Indications
3) By Application: Biliary Sphincterotomy, Biliary Dilatation, Biliary Stenting, Pancreatic Sphincterotomy, Pancreatic Duct Dilatation, Pancreatic Duct Stentin
4) By End User: Hospitals And Clinics, Ambulatory Surgery Centers, Other End Users
Subsegments:
1) By Endoscopes: Flexible Endoscopes, Semi-Rigid Endoscopes, High-Resolution Endoscopes
2) By Endotherapy Devices: Stone Extraction Devices, Balloon Dilatation Catheters, Stents, Biopsy Forceps
3) By Visualization Systems: High-Definition Visualization Systems, Endoscopic Imaging Systems, Video Endoscopes
4) By Energy Devices: Electrosurgical Devices, Laser Devices, Argon Plasma Coagulation Systems
Pre-Book The Endoscopic Retrograde Cholangiopancreatography (ERCP) Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Trends Are Expected To Transform The Endoscopic Retrograde Cholangiopancreatography (ERCP) Market?
Leading firms in the ERCP market are concentrating their efforts on creating cutting-edge technologies like the cholangioscope direct visualisation system. This novel approach aims to offer superior, high-definition visualisation of the bile and pancreatic ducts. As an example, Penlon Limited, a medical device company based in the UK, in July 2024, unveiled the VedVision Cholangioscope Direct Visualisation System. This sophisticated piece of medical equipment offers high-resolution, direct visualisation of the bile and pancreatic ducts, thus improving diagnosis and treatment during ERCP procedures. This system comes with a 2 mm accessory channel and a dedicated guidewire channel that works together with a full range of accessories including biopsy forceps, stone extraction baskets, cytology brushes, and polypectomy snares.
Who Are the Key Players in the Endoscopic Retrograde Cholangiopancreatography (ERCP) Market?
Major companies operating in the endoscopic retrograde cholangiopancreatography (ERCP) market are include:
• Medtronic plc
• Fujifilm Holdings Corporation
• Siemens Healthineers AG
• Stryker Corporation
• Boston Scientific Corporation
• B. Braun Melsungen AG
• Olympus Corporation
• Ottomed Endoscopy
• W. L. Gore & Associates Inc.
• Streis plc
• Cook Group
• KARL STORZ SE & Co. KG
• CONMED Corporation
• PENTAX Medical Inc.
• AMBU Inc.
• Samsung Medison Co. Ltd.
• Medi-Globe GmbH
• Telemed System Inc.
• Micro-Tech Endoscopy Inc.
• Hobbs Medical Inc.
• Shaili Endoscopy Pvt. Ltd.
What Is The Most Dominant Region In The Endoscopic Retrograde Cholangiopancreatography (ERCP) Market?
North America was the largest region in the endoscopic retrograde cholangiopancreatography (ERCP) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the endoscopic retrograde cholangiopancreatography (ERCP) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
